JUPITER: major implications for vascular risk assessment

ABSTRACT

This Editorial comments on the recently published JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), the further evidence it provides for supporting the role of statins in primary prevention and the major implications this may hold for vascular risk assessment and clinical practice guidelines.

Key words: :

• HsCRP
• Primary prevention
• Statins
• Vascular risk assessment

Acknowledgement

Declaration of interest: This editorial was written independently; no company or institution supported it financially. Some of the authors have attended conferences, given lectures and participated in advisory boards or trials sponsored by various pharmaceutical companies (including AstraZeneca, sponsors of the JUPITER trial). No professional writer was involved in the preparation of this editorial.

Konstantinos Tziomalos is supported by a grant from the Hellenic Atherosclerosis Society.